CIDP Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about CIDP clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting

Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Heinrich-Heine University, Duesseldorf35 enrolled2 locationsNCT07273903
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP
argenx160 enrolled19 locationsNCT07091630
Recruiting

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Chronic Inflammatory Demyelinating PolyradiculoneuropathyCIDPCIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
argenx200 enrolled19 locationsNCT07264426
Recruiting

Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Charcot-Marie-ToothCMT1A+2 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta39 enrolled1 locationNCT07461896
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx218 enrolled46 locationsNCT06920004
Recruiting

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Myasthenia GravisCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx279 enrolled4 locationsNCT06299748
Recruiting
Phase 2

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda36 enrolled20 locationsNCT06798012
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Daishi Tian36 enrolled1 locationNCT07337785
Recruiting
Phase 3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda59 enrolled52 locationsNCT06747351
Recruiting
Phase 1

IVIG vs SCIG in CIDP

Chronic Inflammatory Demyelinating PolyneuropathyCIDPImmunoglobulin Deficiency
Rutgers, The State University of New Jersey20 enrolled1 locationNCT05584631
Recruiting

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda30 enrolled15 locationsNCT06538064
Recruiting
Phase 4

Two Dose Levels of Privigen in Pediatric CIDP

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring30 enrolled9 locationsNCT03684018
Recruiting

Biorepository and Registry for Plasma Exchange Patients

NMO Spectrum DisorderCIDPAntibody-mediated Rejection+1 more
Charles M Knudson200 enrolled1 locationNCT05004493
Recruiting

Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study

POEMS SyndromeChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Vasculitic Neuropathy
Rigshospitalet, Denmark520 enrolled1 locationNCT06040567
Recruiting
Phase 2

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CIDP
University of Ulm20 enrolled1 locationNCT04881682
Recruiting
Phase 3

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

CIDP
Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)100 enrolled1 locationNCT06714838
Recruiting
Phase 4

Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
University of Aarhus60 enrolled4 locationsNCT04589299